Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis.
Leibovitzh H, Lee SH, Raygoza Garay JA, Espin-Garcia O, Xue M, Neustaeter A, Goethel A, Huynh HQ, Griffiths AM, Turner D, Madsen KL, Moayyedi P, Steinhart AH, Silverberg MS, Deslandres C, Bitton A, Mack DR, Jacobson K, Cino M, Aumais G, Bernstein CN, Panaccione R, Weiss B, Halfvarson J, Xu W, Turpin W, Croitoru K; Crohn’s and Colitis Canada (CCC) Genetic, Environmental, Microbial (GEM) Project Research Consortium. Leibovitzh H, et al. Gut. 2023 Aug;72(8):1462-1471. doi: 10.1136/gutjnl-2022-328421. Epub 2023 Feb 14. Gut. 2023. PMID: 36788016
Helicobacter pylori infection is positively associated with an increased BMI, irrespective of socioeconomic status and other confounders: a cohort study.
Suki M, Leibovici Weissman Y, Boltin D, Itskoviz D, Tsadok Perets T, Comaneshter D, Cohen A, Niv Y, Dotan I, Leibovitzh H, Levi Z. Suki M, et al. Among authors: leibovitzh h. Eur J Gastroenterol Hepatol. 2018 Feb;30(2):143-148. doi: 10.1097/MEG.0000000000001014. Eur J Gastroenterol Hepatol. 2018. PMID: 29120907
Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk.
Lee SH, Turpin W, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, Goethel A, Turner D, Mack D, Deslandres C, Cino M, Aumais G, Panaccione R, Jacobson K, Bitton A, Steinhart AH, Huynh HQ, Princen F, Moayyedi P, Griffiths AM, Silverberg MS, Paterson AD, Xu W, Croitoru K; Crohn’s and Colitis Canada Genetics Environment Microbial Project Research Consortium. Lee SH, et al. Among authors: leibovitzh h. Gastroenterology. 2021 Nov;161(5):1540-1551. doi: 10.1053/j.gastro.2021.07.009. Epub 2021 Jul 20. Gastroenterology. 2021. PMID: 34293299
Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation.
Turpin W, Dong M, Sasson G, Raygoza Garay JA, Espin-Garcia O, Lee SH, Neustaeter A, Smith MI, Leibovitzh H, Guttman DS, Goethel A, Griffiths AM, Huynh HQ, Dieleman LA, Panaccione R, Steinhart AH, Silverberg MS, Aumais G, Jacobson K, Mack D, Murthy SK, Marshall JK, Bernstein CN, Abreu MT, Moayyedi P, Paterson AD; Crohn’s and Colitis Canada (CCC) Genetic, Environmental, Microbial (GEM) Project Research Consortium; Xu W, Croitoru K. Turpin W, et al. Among authors: leibovitzh h. Gastroenterology. 2022 Sep;163(3):685-698. doi: 10.1053/j.gastro.2022.05.037. Epub 2022 May 26. Gastroenterology. 2022. PMID: 35643175
Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn's Disease.
Leibovitzh H, Lee SH, Xue M, Raygoza Garay JA, Hernandez-Rocha C, Madsen KL, Meddings JB, Guttman DS, Espin-Garcia O, Smith MI, Goethel A, Griffiths AM, Moayyedi P, Steinhart AH, Panaccione R, Huynh HQ, Jacobson K, Aumais G, Mack DR, Abreu MT, Bernstein CN, Marshall JK, Turner D, Xu W; CCC GEM Project Research Consortium; Turpin W, Croitoru K. Leibovitzh H, et al. Gastroenterology. 2022 Nov;163(5):1364-1376.e10. doi: 10.1053/j.gastro.2022.07.004. Epub 2022 Jul 16. Gastroenterology. 2022. PMID: 35850197
Reply.
Leibovitzh H, Turpin W, Croitoru K. Leibovitzh H, et al. Gastroenterology. 2023 May;164(6):1026-1027. doi: 10.1053/j.gastro.2023.01.012. Epub 2023 Jan 16. Gastroenterology. 2023. PMID: 36657530 No abstract available.
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N; Alimentiv Translational Research Consortium (ATRC). Verstockt B, et al. Among authors: leibovitzh h. Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):433-446. doi: 10.1038/s41575-023-00768-1. Epub 2023 Apr 17. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37069321 Review.
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.
Cohen NA, Plevris N, Kopylov U, Grinman A, Ungar B, Yanai H, Leibovitzh H, Isakov NF, Hirsch A, Ritter E, Ron Y, Shitrit AB, Goldin E, Dotan I, Horin SB, Lees CW, Maharshak N. Cohen NA, et al. Among authors: leibovitzh h. United European Gastroenterol J. 2020 Nov;8(9):1076-1085. doi: 10.1177/2050640620951400. Epub 2020 Aug 17. United European Gastroenterol J. 2020. PMID: 32807038 Free PMC article.
Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable.
Yanai H, Goren I, Godny L, Maharshak N, Ron Y, Avni Biron I, Leibovitzh H, Banai Eran H, Aharoni Golan M, Rabinowitz K, Ziv Baran T, Lavie I, Yadgar K, Zonensain K, Kopylov U, Ben Horin S, Eliakim R, Waterman M, Chowers Y, Ben-Shachar S, Dotan I; Israeli IBD Research Nucleus. Yanai H, et al. Among authors: leibovitzh h. Clin Gastroenterol Hepatol. 2021 Aug;19(8):1564-1572.e5. doi: 10.1016/j.cgh.2020.06.069. Epub 2020 Jul 3. Clin Gastroenterol Hepatol. 2021. PMID: 32629126
20 results